Company: HURA
Filing Date: 2025-06-06
Form Type: 425
Source: 0001193125-25-137145
Chunk: 72

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-06-06
Form: 425
Chunk 72
---
, for an aggregate of 4.6 million shares, together with warrants to purchase an equal number shares of common stock at an exercise price of $3.3125 per warrant share. The securities in the offering were sold at a combined purchase price of $2.65 per share and accompanying warrant, which represents a fifteen percent (15%) discount to the NASDAQ closing price of the Company’s common stock on June 2, 2025. Under the definitive agreement, approximately $9.0 million of the total offering amount will be purchased in four equal tranches based on the Company’s achievement of certain milestones (the “Initial Funding Amount”), and the remaining $3.5 million is required to be purchased and funded by December 31, 2025. One-fourth of the Initial Funding Amount will be purchased and funded at the initial closing of the offering, which is anticipated to be held on June 4, 2025 (subject to customary closing conditions), with the remaining three tranches of the Initial Funding Amount to be purchased and funded based on the achievement of the following three milestones (the “Funding Milestones”) if and when the applicable milestone is achieved:

| • |     | One-fourth of the Initial Funding Amount will be purchased and funded after the Company’s Phase 3 trial for 
 IFx-Hu2.0 has been initiated; and                                                                           |

| • |     | One-fourth of the Initial Funding Amount will be purchased and funded immediately prior to the closing of the 
 Company’s proposed merger transaction with Kineta, Inc. (the “Kineta Merger”).                                |

The Company currently anticipates that all of the Funding Milestones will be achieved by the end of July 2025. The warrants issued in the offering will expire on the fifth (5th) anniversary of the initial exercise date, with the initial exercise date being the later of (i) six months from the date of the definitive securities purchase agreement or (ii) the amendment of the Company’s articles of incorporation to increase the number of authorized shares of common stock. The exercise price of the warrants is subject to proportional adjustment for stock splits, reverse stock splits, and similar transactions. The Company currently plans to use the net proceeds from the offering to fund cash requirements for the closing the proposed merger with Kineta, Inc., to fund the initiation of the Phase 3 Trial for IFx-2.0,to fund the advancement of Kineta’s KVA12123 novel VISTA-inhibiting antibody to a Phase